Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the causal factors? Can it be avoided?

Natalizumab (Tysabri®) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, three patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with pro...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Warnke, Clemens, Menge, Til, Hartung, Hans-Peter, Racke, Michael K., Cravens, Petra D., Bennett, Jeffrey L., Frohman, Elliot M., Greenberg, Benjamin M., Zamvil, Scott S., Gold, Ralf, Hemmer, Bernhard, Kieseier, Bernd C., Stüve, Olaf
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157908/
https://ncbi.nlm.nih.gov/pubmed/20697042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2010.161
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items